– Green light for a sale of Doliprane to an American fund
The best-selling drug in France, Doliprane will be sold by the pharmaceutical group Sanofi to an American investment fund.
Published today at 10:50 p.m.
Doliprane is the best-selling drug in France.
AFP
Subscribe now and enjoy the audio playback feature.
BotTalk
An agreement has been reached between the French State, the pharmaceutical group Sanofi and the American investment fund CD&R for the acquisition by the latter of the subsidiary marketing Doliprane, the best-selling drug in France, the French Ministry of Health announced on Sunday. the Economy.
The French Minister of the Economy Antoine Armand assured on
At this point you will find additional external content. If you accept that cookies are placed by external providers and that personal data is thus transmitted to them, you must allow all cookies and display external content directly.
Allow cookiesMore info
“Our demands on employment, production and investment will be respected. For Doliprane and other essential medicines for the country,” he added. “We have reached the highest possible level of guarantees in the discussions” with Sanofi on this issue, specified the offices of the Ministers of Economy and Industry. The French State, via the Bpifrance bank, “will be a shareholder to ensure this”, they specified.
Sensitive file
The issue remains sensitive in a context of recurring shortages of medicines in the country. The State has thus obtained “guarantees” on employment, production, supply of the French market, governance and development of the company, underline these sources who will detail these commitments Monday morning during a conference press.
Sanofi, in discussions on a possible sale of Opella to the CD&R fund since October 11, also announced a separate communication Monday morning. The pharmaceutical giant is thus taking a new step in this separation project aimed at allowing it to focus on innovation in immunology, rare diseases and vaccines, more profitable areas, but where it will need to invest.
He plans to remain a 50% shareholder in Opella’s next capital structure, valued by business media at around 15 billion euros (14 billion francs). The French investment fund PAI Partners, in partnership with international co-investors, was a candidate for the buyout and had improved its offer on Thursday, in vain.
Right of inspection
CD&R has been investing in France for around fifteen years (notably in Rexel, Spie, Socotec, But and Conformama) and supports several pharmaceutical companies such as Inizio and Sharp.
The participation of the public investment bank Bpifrance in the operation, recorded on Sunday evening, is a means for the government to obtain a right of review over the strategic orientations taken by the new foreign shareholder.
The pharmaceutical group has ensured since day one that “this project will have no impact on employment in France” and that it aims to grow Opella by relying on a financial partner ready to invest in this market. closer to mass consumption than to pharmaceutical activity.
“Latest news”
Want to stay on top of the news? “Tribune de Genève” offers you two meetings per day, directly in your email box. So you don’t miss anything that’s happening in your canton, in Switzerland or around the world.
Other newsletters
Log in
AFP
Did you find an error? Please report it to us.
0 comments
